How Biotech Firms Kept Raw Material Shortages From Affecting Patients During Pandemic
Biogen, Amgen, Lilly and Genentech experts shared tales of impending stockouts, particularly for single-use assemblies, filters and resins, and some of the measures they took to prevent them from causing drug shortages.
You may also be interested in...
Distress grows as manufacturers wait for suppliers to boost production. One idea: stretch inventories by qualifying single-use bioreactors for reuse.
Proposed guidance revision adds nuance to manufacturing facility separation expectations for beta-lactam compounds that pose less risk of anaphylaxis than penicillin and related antibiotics.
All-out efforts by agency staff to help industry supply COVID-19 treatments last year were applauded but now its attention returns to the top pre-pandemic priority, contamination risks. Edge Pharma consents to attack mold, Glicerinas blocked over inspection refusal, Bioiberica hit for ‘reprocessing’ contaminated drug substance, Rentschler bashed for inadequate monitoring.